192 related articles for article (PubMed ID: 31891764)
1. Pre-transplant assessment of pp65-specific CD4 T cell responses identifies CMV-seropositive patients treated with rATG at risk of late onset infection.
López-Oliva MO; Martínez V; Rodríguez-Sanz A; Álvarez L; Santana MJ; Selgas R; Jiménez C; Bellón T
Clin Immunol; 2020 Feb; 211():108329. PubMed ID: 31891764
[TBL] [Abstract][Full Text] [Related]
2. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant.
López-Oliva MO; Martinez V; Buitrago A; Jiménez C; Rivas B; Escuin F; Santana MJ; Selgas R; Bellón T
Transplantation; 2014 Apr; 97(8):839-45. PubMed ID: 24345896
[TBL] [Abstract][Full Text] [Related]
3. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
4. Rapid T cell repopulation after rabbit anti-thymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus.
Havenith SH; Remmerswaal EB; Bemelman FJ; Yong SL; van Donselaar-van der Pant KA; van Lier RA; Ten Berge IJ
Clin Exp Immunol; 2012 Sep; 169(3):292-301. PubMed ID: 22861369
[TBL] [Abstract][Full Text] [Related]
5. Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: A pilot study.
Martín-Gandul C; Pérez-Romero P; Mena-Romo D; Molina-Ortega A; González-Roncero FM; Suñer M; Bernal G; Cordero E;
Transpl Infect Dis; 2018 Jun; 20(3):e12883. PubMed ID: 29570917
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.
Egli A; Binet I; Binggeli S; Jäger C; Dumoulin A; Schaub S; Steiger J; Sester U; Sester M; Hirsch HH
J Transl Med; 2008 Jun; 6():29. PubMed ID: 18541023
[TBL] [Abstract][Full Text] [Related]
7. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
Limaye AP; Green ML; Edmison BC; Stevens-Ayers T; Chatterton-Kirchmeier S; Geballe AP; Singh N; Boeckh M
J Infect Dis; 2019 Jul; 220(5):752-760. PubMed ID: 31112280
[TBL] [Abstract][Full Text] [Related]
8. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
[TBL] [Abstract][Full Text] [Related]
9. CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy.
Mena-Romo JD; Pérez Romero P; Martín-Gandul C; Gentil MÁ; Suárez-Artacho G; Lage E; Sánchez M; Cordero E
J Infect; 2017 Oct; 75(4):336-345. PubMed ID: 28599954
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
12. CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.
Jarque M; Melilli E; Crespo E; Manonelles A; Montero N; Torras J; Cruzado JM; Luque S; Gil-Vernet S; Grinyó JM; Bestard O
Transplantation; 2018 Nov; 102(11):e472-e480. PubMed ID: 30130330
[TBL] [Abstract][Full Text] [Related]
13. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection.
Eid AJ; Brown RA; Arthurs SK; Lahr BD; Eckel-Passow JE; Larson TS; Razonable RR
Transpl Int; 2010 May; 23(5):506-13. PubMed ID: 19951371
[TBL] [Abstract][Full Text] [Related]
14. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.
Fernández-Ruiz M; Giménez E; Vinuesa V; Ruiz-Merlo T; Parra P; Amat P; Montejo M; Paez-Vega A; Cantisán S; Torre-Cisneros J; Fortún J; Andrés A; San Juan R; López-Medrano F; Navarro D; Aguado JM;
Clin Microbiol Infect; 2019 Mar; 25(3):381.e1-381.e10. PubMed ID: 29803844
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients.
Carbone J; Lanio N; Gallego A; Kern F; Navarro J; Muñoz P; Alonso R; Catalán P; Fernández-Yáñez J; Palomo J; Ruiz M; Fernández-Cruz E; Sarmiento E
J Clin Immunol; 2012 Aug; 32(4):809-19. PubMed ID: 22371292
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of cytomegalovirus-specific T-cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study.
Jacobs SE; Ibrahim U; Vega AB; Lagdameo J; Callahan J; Govindarajulu U; Gitman M; Levine JE; Rana M; Keyzner A
Transpl Infect Dis; 2024 Jun; 26(3):e14290. PubMed ID: 38708941
[TBL] [Abstract][Full Text] [Related]
17. Dynamics and Clinical Significance of Cytomegalovirus-Specific Neutralizing Antibodies in Kidney Transplant Recipients Treated with T-Cell-Depleting Agents.
Fernández-Ruiz M; García-Ríos E; Redondo N; Rodríguez-Goncer I; Ruiz-Merlo T; Parra P; Sandonis V; López-Medrano F; San Juan R; González E; Polanco N; Andrés A; Navarro D; Aguado JM; Pérez-Romero P
J Infect Dis; 2024 Jun; 229(6):1812-1816. PubMed ID: 37740549
[TBL] [Abstract][Full Text] [Related]
18. Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients.
Calarota SA; Chiesa A; Scaramuzzi L; Adzasehoun KM; Comolli G; Mangione F; Esposito P; Baldanti F
J Clin Virol; 2014 Sep; 61(1):65-73. PubMed ID: 24961915
[TBL] [Abstract][Full Text] [Related]
19. Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.
Snyder LD; Medinas R; Chan C; Sparks S; Davis WA; Palmer SM; Weinhold KJ
Am J Transplant; 2011 Mar; 11(3):553-60. PubMed ID: 21219584
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease.
La Rosa C; Limaye AP; Krishnan A; Longmate J; Diamond DJ
J Infect Dis; 2007 Mar; 195(5):633-44. PubMed ID: 17262704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
